The global glaucoma treatment market holds a valuation of US$ 5.7 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.18%, and is expected to hold a market value of around US$ 8.0 Billion in 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 5.7 Billion |
| Market Value 2023 | US$ 5.8 Billion |
| Market Value 2033 | US$ 8.0 Billion |
| CAGR 2023 to 2033 | 3.2% |
| Market Share of Top 5 Countries (2022) | 55.2% |
| Key Market Players | AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. |
Glaucoma is the most common and second leading eye diseases and causes irreversible blindness by damaging optic nerve by high eye pressure. The common glaucoma type is open angle glaucoma causes vision loss with no apparent symptoms, while angle closure glaucoma is infrequent glaucoma and occurs with symptoms like eye pain with visual disturbance, and nausea. Glaucoma aetiology includes age-related macular degeneration, cataract, diabetic retinopathy, glaucoma, uncorrected refractive errors, and other factors.
According to the World Health Organization (WHO), about 4.5 million people suffers from glaucoma globally in 2019. As per published data of National Glaucoma Research data in 2022, currently glaucoma patients are more than 80 million and it is anticipated to increase beyond 111 million till 2040.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The glaucoma treatment industry expanded at a CAGR of 3.0% for 2017 to 2022 period due to increasing prevalence of glaucoma disease and diabetes, old - age population, and innovative technologies with novel pharmacological discoveries.
The global glaucoma treatment market contributes 15.9% value share to the global eye disorders and treatment market valued at US$ 35.8 Billion in 2022.
The glaucoma condition is frequently known as silent thief of sigh since most of the glaucoma variations rarely show pain or other obvious signs before causing noticeable vision loss; hence, number of glaucoma cases are rising. Government and pharmaceutical company activities are raising awareness of glaucoma are promoting the expansion of the market for glaucoma treatments.
Another factor driving the expansion of the market of glaucoma treatment is technological development in eye drops, which are the primary glaucoma control measure. Pharmaceutical and biotech businesses are also investing in the creation of novel glaucoma products. The most common medications used to treat glaucoma today include alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogues, and combinations of these drugs. In contrast, the absence of discomfort and symptoms other than apparent vision loss are regarded as a problem for the market of glaucoma treatment.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 2.44% |
| Jul-Dec (H2), 2021 (A) | 3.55% |
| Jan-Jun (H1),2022 Projected (P) | 2.33% |
| Jan-Jun (H1),2022 Outlook (O) | 2.57% |
| Jul-Dec (H2), 2022 Outlook (O) | 3.39% |
| Jul-Dec (H2), 2022 Projected (P) | 3.19% |
| Jan-Jun (H1), 2023 Projected (P) | 2.70% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 24 ↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 13 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 20 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | (-) 17 ↓ |
Principal Consultant
Rising elderly populations and glaucoma awareness in several countries, as well as an increase in government and private sector initiatives to cure glaucoma and reduce the financial treatment cost, are expected to drive the glaucoma market demand.
An increase in the number of new innovative products and clinical trial products is boosting the industry's growth. The University of Minnesota College of Pharmacy's Department of Medicinal Chemistry and the Institute for Therapeutics Discovery & Development (ITDD) collaborated to create a novel medicine for the treatment of glaucoma in 2022.
The market is primarily driven by the ophthalmology industry's rapid technical advancements and the growing use of innovative surgical methods. The need for optometrists has grown as a result of advancements in optical coherence tomography (OCT), selective laser trabeculoplasty (SLT), medical imaging, progression analysis software, and microinvasive glaucoma surgery (MIGS). This is one of the key driving forces for the market's expansion. The size of the glaucoma market is anticipated to increase with the introduction of laser therapy and pharmaceuticals for the condition.
It is challenging to treat glaucoma because it does not initially cause symptoms like pain or vision loss. Glaucoma surgery also frequently results in a number of post-operative problems. Shortage of experienced healthcare workers and a lack of knowledge about glaucoma treatment in emerging nations may impede the growth of the industry of glaucoma treatment in the years to come.
The glaucoma drug approval process is stringent, and sometimes need to remove or reject a product from market due to safety issues concerns and also, by various other reasons, including bioavailability, drug performance, efficacy, PH properties, toxicity. Apotex Corp, for example, is recalling 22,027 bottles of timolol maleate ophthalmic solution in 2023 due to drug samples failed to meet stability specifications.
Drug side effects are also associated with glaucoma treatment. Prostaglandin analogues, for example, have side effects such as eye redness and itching; beta blockers have side effects such as low blood pressure and decreased libido; and Rho kinase inhibitors have side effects such as stinging and small bleeds on the white part of the eye.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 29.7% |
| Market Share (2033) | 29.8% |
| BPS Analysis | 9 |
| Country | China |
|---|---|
| Market Share (2023) | 11.1% |
| Market Share (2033) | 11.3% |
| BPS Analysis | 21 |
| Country | Russia |
|---|---|
| Market Share (2023) | 5.6% |
| Market Share (2033) | 5.7% |
| BPS Analysis | 1 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 5.4% |
| BPS Analysis | 25 |
| Country | Canada |
|---|---|
| Market Share (2023) | 4.1% |
| Market Share (2033) | 3.9% |
| BPS Analysis | -19 |
The USA will dominate the global market of glaucoma treatment in 2023 with a market share of 29.7% in global glaucoma treatment market. The rising prevalence of various types of glaucoma in the region would boost the demand for glaucoma therapies.
The market will grow as more people become aware of the importance of eye care and the associated diagnoses and treatments. The region's significant presence of important market companies involved in new drug research and product approvals would boost regional industry growth.
Due to the increased glaucoma incidence and improved healthcare infrastructure, the United States is likely to be the largest glaucoma treatment industry. According to the BrightFocus Foundation, more than 3 million Americans are affected by glaucoma, with open-angle glaucoma being the most frequent type.
Glaucoma costs the USA economy around USD 2.86 billion in direct costs and productivity losses each year. Many organizations in the United States are raising awareness of glaucoma, which is projected to boost the market's overall growth.
Germany will hold the market share of 5.2% for its glaucoma treatment in 2023 global market.
Glaucoma is one of the leading causes of blindness in the world. Around 500,000 people in Germany have high intraocular pressure, and 10% of them are at risk of going blind. The number of unreported cases, however, is likely to be even higher. Glaucoma affects both men and women at a younger age. Acute glaucoma can strike at any age, but the risk rises significantly with age. Women are more vulnerable than men.
According to hospital quality reports, glaucoma treatment in Germany became more efficient from classical to modern treatment procedures after 2006, and it became a potential for stringent repayment guidelines.
The Indian Glaucoma treatment sector is expected to grow at a CAGR of 4.3% between 2023 and 2033.
Market expansion is fuelled by the rising elderly population as well as innovations in glaucoma and cataract surgery equipment technology. The development of micro-invasive glaucoma drainage implants, which are used to treat glaucoma and offer a safer and less intrusive means of reducing intraocular pressure (IOP) as compared to standard glaucoma surgery devices, is another area where manufacturers are placing more emphasis.
However, a shortage of qualified experts, a refusal to pay for the use of glaucoma and cataract surgical tools, and the exorbitant cost of cataract operation, particularly in emerging economies hinder market expansion. The government and other charitable groups' efforts to educate the public about the advantages of cataract surgery, eye problems, and the availability of cutting-edge technology have also opened up lucrative market potential in India.
Open angle Glaucoma disease type will contribute market share for about 81.35% in 2023 global market and it is expected to be stable through the forecast.
The most common type of glaucoma in the population is primary open angle glaucoma (POAG). According to a glaucoma genetics article published in the human molecular genetics journal, more than 57.5 million people worldwide were affected by POAG in 2020, with a global prevalence of 2.2%. As a result, rising glaucoma disease burden is expected to provide lucrative market growth opportunities.
The development of biologics is one of the main open angle glaucoma therapeutics industry trends driving market expansion. Several biologics are being developed for the treatment of open angle glaucoma. These drugs are expected to be more effective and safer than small molecules. As a result, it is expected that the development of such new biologics for the treatment of open angle glaucoma will meet the unmet need for an innovative and secure treatment of open-angle glaucoma, assisting the market to expand to a certain amount over the forecast period.
The prostaglandin analogue sector will hold a 33.36% market share in the global market for treating glaucoma in 2023 because ophthalmic drugs are becoming more widely accessible and available. Prostaglandin analogues are widely used to lower intraocular pressure due to their effectiveness, once-daily dose, lack of adverse effects, and improved recovery rates in the treatment of glaucoma, which will drive market demand. It is also projected that rising demand for prostaglandin medications in combination therapy would present the market with significant potential prospects. The overall market statistics will be further boosted by growing consumer awareness of early glaucoma therapy and an increase in the number of patients receiving early eye illness diagnosis.
Hospital pharmacies segment will hold the market share of 56.55% in 2023 globally. The demand for hospital pharmacies will be boosted by the increased availability of innovative medications.
In 2022, the hospital pharmacy segment was worth more than USD 3 billion. Throughout the analysis, the segment is expected to grow significantly. The significant growth is due to the widespread availability of products in various settings for various forms of glaucoma therapy.
Patient's preference for hospital pharmacies for prescribed medications also contributes to income growth. Reimbursement rules and insurance coverage for drug purchases made in hospital settings are also expected to improve market predictions.
The key companies in the glaucoma treatment are concentrating their efforts on partnerships and collaborations as the primary means of increasing their geographical presence. These will aid market participants in expanding both their new product launch and market penetration.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the glaucoma treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Disease Type, Drug Class, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market of glaucoma treatment is worth US$ 5.7 Billion in 2022 and is set to expand 1.4X over the next ten years.
The global market in estimated to reach a valuation of US$ 5.8 Billion in 2023.
Between 2017 and 2022, the global market expanded at the rate of 3.0%.
The market of glaucoma treatment is expected to reach US$ 8.0 Billion by the end of 2033, with sales revenue expected to register 3.2% CAGR.
The global market is projected to expand at a CAGR of around 3.2% between 2023 and 2033.
The USA, China, Russia, Germany, and Canada are expected to drive demand for glaucoma treatment sector; and the market share of these top 5 countries will be 55.2% for the year 2022.
Europe is set to hold around 30.0% market share in the global market of glaucoma treatment in 2023.
AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. are the key players of glaucoma treatment market.
Open angle Glaucoma disease type presents market share for about 81.35% in 2023 global market.
North America is one of the key markets for glaucoma treatment sector, with the USA to account for about 29.7% of the global glaucoma treatment sector in the year 2023.
The market is valued at US$ 5.8 billion in 2023.
A 3.2% CAGR is expected between 2023 and 2033 for the market.
In 2022, the top 5 countries held 55.2% of the market share.
The United States is estimated to generate a 29.8% share by 2033.
Open and glaucoma disease is to hold an 81.35% share in 2023.
1. Executive Summary | Glaucoma Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption/Usage Analysis
4.2. Key Promotional Strategies, by Manufacturers
4.3. Key Regulations
4.4. PESTEL Analysis
4.5. Porter’s Analysis
4.6. Disease Epidemiology
4.7. Pipeline Assessment
4.8. Reimbursement
4.9. Supply Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Eye Disorders & Diseases Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical & Current Growth
5.2.2. New Drug Launches and Approvals
5.2.3. Global Ophthalmic Epidemiology
5.2.4. R&D Expenditure by Key Players
5.2.5. Rising Consumer Awareness of the Eye Health
5.2.6. Rising Adoption of Glaucoma Treatment
5.2.7. Strategic Developments by Key Players
5.2.8. Increased Adoption of Therapies for Glaucoma
5.2.9. Strategic Collaborations among Players
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Disease Type
6.1.2. By Drug Class
6.1.3. By Distribution Channel
6.1.4. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis by Disease Type, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Disease Type, 2023 to 2033
8.3.1. Open Angle Glaucoma
8.3.2. Angle Closure Glaucoma
8.3.3. Other
8.4. Market Attractiveness Analysis by Disease Type
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis by Drug Class, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Drug Class, 2023 to 2033
9.3.1. Prostaglandin Analog
9.3.2. Beta Blockers
9.3.3. Adrenergic Agonist
9.3.4. Carbonic Anhydrase Inhibitors
9.3.5. Others
9.4. Market Attractiveness Analysis by Drug Class
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis by Distribution Channel, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Distribution Channel, 2023 to 2033
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Attractiveness Analysis by Distribution Channel
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, by Region, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East & Africa
11.4. Market Attractiveness Analysis by Region
12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. The USA
12.3.1.2. Canada
12.3.2. By Disease Type
12.3.3. BY Drug Class
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Disease Type
12.4.3. By Drug Class
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Disease Type
12.8.1.2.2. By Drug Class
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Disease Type
12.8.2.2.2. By Drug Class
12.8.2.2.3. By Distribution Channel
13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Disease Type
13.3.3. By Drug Class
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Disease Type
13.4.3. By Drug Class
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Disease Type
13.8.1.2.2. By Drug Class
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Disease Type
13.8.2.2.2. By Drug Class
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Disease Type
13.8.3.2.2. By Drug Class
13.8.3.2.3. By Distribution Channel
14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. United Kingdom (UK)
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Disease Type
14.3.3. By Drug Class
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Disease Type
14.4.3. By Drug Class
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Disease Type
14.8.1.2.2. By Drug Class
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Disease Type
14.8.2.2.2. By Drug Class
14.8.2.2.3. By Distribution Channel
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Disease Type
14.8.3.2.2. By Drug Class
14.8.3.2.3. By Distribution Channel
14.8.4. United Kingdom Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Disease Type
14.8.4.2.2. By Drug Class
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Disease Type
14.8.5.2.2. By Drug Class
14.8.5.2.3. By Distribution Channel
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Disease Type
14.8.6.2.2. By Drug Class
14.8.6.2.3. By Distribution Channel
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Disease Type
14.8.7.2.2. By Drug Class
14.8.7.2.3. By Distribution Channel
15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Disease Type
15.3.3. By Drug Class
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Disease Type
15.4.3. By Drug Class
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Disease Type
15.8.1.2.2. By Drug Class
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Disease Type
15.8.2.2.2. By Drug Class
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Disease Type
15.8.3.2.2. By Drug Class
15.8.3.2.3. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Disease Type
16.3.3. By Drug Class
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Disease Type
16.4.3. By Drug Class
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Disease Type
16.8.1.2.2. By Drug Class
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Disease Type
16.8.2.2.2. By Drug Class
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Disease Type
16.8.3.2.2. By Drug Class
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Disease Type
16.8.4.2.2. By Drug Class
16.8.4.2.3. By Distribution Channel
17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Disease Type
17.3.3. By Drug Class
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Disease Type
17.4.2. By Drug Class
17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Disease Type
17.8.1.2.2. By Drug Class
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Disease Type
17.8.2.2.2. By Drug Class
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. North Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Disease Type
18.3.3. By Drug Class
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Disease Type
18.4.3. By Drug Class
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Disease Type
18.8.1.2.2. By Drug Class
18.8.1.2.3. By Distribution Channel
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Disease Type
18.8.2.2.2. By Drug Class
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Disease Type
18.8.3.2.2. By Drug Class
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Disease Type
18.8.4.2.2. By Drug Class
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. AERIE Pharmaceuticals, Inc.
20.3.1.1. Overview
20.3.1.2. Drug Type Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Key Financials
20.3.1.5. SWOT Analysis
20.3.1.6. Key Developments
20.3.1.7. Strategy Overview
20.3.1.7.1. Marketing Strategy
20.3.1.7.2. Product Type Strategy
20.3.1.7.3. Channel Strategy
20.3.2. Cipla Inc.
20.3.2.1. Overview
20.3.2.2. Drug Type Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Key Financials
20.3.2.5. SWOT Analysis
20.3.2.6. Key Developments
20.3.2.7. Strategy Overview
20.3.2.7.1. Marketing Strategy
20.3.2.7.2. Product Type Strategy
20.3.2.7.3. Channel Strategy
20.3.3. Akorn Operating Company LLC
20.3.3.1. Overview
20.3.3.2. Drug Type Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Key Financials
20.3.3.5. SWOT Analysis
20.3.3.6. Key Developments
20.3.3.7. Strategy Overview
20.3.3.7.1. Marketing Strategy
20.3.3.7.2. Product Type Strategy
20.3.3.7.3. Channel Strategy
20.3.4. AbbVie
20.3.4.1. Overview
20.3.4.2. Drug Type Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Key Financials
20.3.4.5. SWOT Analysis
20.3.4.6. Key Developments
20.3.4.7. Strategy Overview
20.3.4.7.1. Marketing Strategy
20.3.4.7.2. Product Type Strategy
20.3.4.7.3. Channel Strategy
20.3.5. Bausch & Lomb Incorporated
20.3.5.1. Overview
20.3.5.2. Drug Type Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Key Financials
20.3.5.5. SWOT Analysis
20.3.5.6. Key Developments
20.3.5.7. Strategy Overview
20.3.5.7.1. Marketing Strategy
20.3.5.7.2. Product Type Strategy
20.3.5.7.3. Channel Strategy
20.3.6. Inoteck Pharmaceuticals
20.3.6.1. Overview
20.3.6.2. Drug Type Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Key Financials
20.3.6.5. SWOT Analysis
20.3.6.6. Key Developments
20.3.6.7. Strategy Overview
20.3.6.7.1. Marketing Strategy
20.3.6.7.2. Product Type Strategy
20.3.6.7.3. Channel Strategy
20.3.7. Merck & Co. Inc.
20.3.7.1. Overview
20.3.7.2. Drug Type Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Key Financials
20.3.7.5. SWOT Analysis
20.3.7.6. Key Developments
20.3.7.7. Strategy Overview
20.3.7.7.1. Marketing Strategy
20.3.7.7.2. Product Type Strategy
20.3.7.7.3. Channel Strategy
20.3.8. Novartis AG
20.3.8.1. Overview
20.3.8.2. Drug Type Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Key Financials
20.3.8.5. SWOT Analysis
20.3.8.6. Key Developments
20.3.8.7. Strategy Overview
20.3.8.7.1. Marketing Strategy
20.3.8.7.2. Product Type Strategy
20.3.8.7.3. Channel Strategy
20.3.9. Pfizer Inc.
20.3.9.1. Overview
20.3.9.2. Drug Type Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Key Financials
20.3.9.5. SWOT Analysis
20.3.9.6. Key Developments
20.3.9.7. Strategy Overview
20.3.9.7.1. Marketing Strategy
20.3.9.7.2. Product Type Strategy
20.3.9.7.3. Channel Strategy
20.3.10. Santen Pharmaceutical Co. Ltd.
20.3.10.1. Overview
20.3.10.2. Drug Type Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Key Financials
20.3.10.5. SWOT Analysis
20.3.10.6. Key Developments
20.3.10.7. Strategy Overview
20.3.10.7.1. Marketing Strategy
20.3.10.7.2. Product Type Strategy
20.3.10.7.3. Channel Strategy
20.3.11. Teva Pharmaceutical Industries Ltd.
20.3.11.1. Overview
20.3.11.2. Drug Type Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Key Financials
20.3.11.5. SWOT Analysis
20.3.11.6. Key Developments
20.3.11.7. Strategy Overview
20.3.11.7.1. Marketing Strategy
20.3.11.7.2. Product Type Strategy
20.3.11.7.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Glaucoma Treatment Market
